Leukemia Research
Volume 26, Issue 8 , Pages 713-720 , August 2002

Bcr–Abl variants: biological and clinical aspects

  • Anjali S. Advani

      Affiliations

    • Departments of Hematology and Oncology, Duke University Medical Center, Durham, NC 27710, USA
    • ,
  • Ann Marie Pendergast

      Affiliations

    • Department of Pharmacology and Cancer Biology, LSRC Room C233A, La Salle St. Extension, Duke University Medical Center, Durham, NC 27710, USA
    • Corresponding Author InformationCorresponding author. Fax: +1-919-681-7148

Received 8 November 2001 ,Accepted 25 November 2001.

References 

  1. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giesma staining. Nature. 1973;243:290
  2. Melo JV. The diversity of BCR–ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375
  3. Zhang X, Rong R, Hao SX, Pear WS, Ren R. The SH2 domain of Bcr–Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood. 2001;97:277
  4. Sawyers CL. Chronic myeloid leukemia. N. Engl. J. Med. 1999;340:1330
  5. Goldman JM. Chronic myeloid leukemia. Curr. Opin. Hematol. 1997;4:277
  6. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N. Engl. J. Med. 1999;341:164
  7. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology. 1999;13:169
  8. Kantarjian HM, Deisseroth A, Kurzrock R, et al.  Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691
  9. Cortes J, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am. J. Med. 1996;100:555
  10. Kantarjian H, Dixon D, Keating MJ, et al.  Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441
  11. Griffin JD, Todd RF, Ritz J, et al.  Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983;61:85
  12. Kantarjian HM, Keating MJ, Talpaz M, et al.  Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am. J. Med. 1987;83:445
  13. Thijsen S, Schuurhuis G, van Oostveen J, Ossenkoppele G. Chronic myeloid leukemia from basics to bedside. Leukemia. 1999;13:1646
  14. Derderian PM, Kantarjian HM, Talpaz M, O’Brien S, Cork A, Estey E, et al.  Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am. J. Med. 1993;94:69
  15. Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, et al.  Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 1992;10:398
  16. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, et al.  Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988;62:672
  17. Hoelzer D. Therapy and prognostic factors in adult acute lymphoblastic leukemia. Baillieres. Clin. Haematol. 1994;7:299
  18. Hooberman A, Westbrook C, Spino C, et al.  Clinical significance of molecular detection of the BCR–ABL fusion gene in acute lymphoblastic leukemia (ALL): a Cancer and Leukemia Group B (CALGB) study. Proc. Am. Soc. Clin. Oncol. 1991;10:222
  19. Spencer A, O’Brien SG, Goldman JM. Options for therapy in chronic myeloid leukaemia. Br. J. Haematol. 1995;91:2
  20. Pui CH, Evans WE. Acute lymphoblastic leukemia. N. Engl. J. Med. 1998;339:605
  21. Allen PB, Morgan GJ, Wiedemann LM. Philadelphia chromosome-positive leukemia: the translocated genes and their gene products. Baillieres. Clin. Haematol. 1992;5:897
  22. Reardon DA, Hanson CA, Roth MS, Castle VP. Lineage switch in Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 1994;73:1526
  23. Abe R, Ishibashi T, Kimura H, et al.  The significance of cytogenetic findings of erythroid colonies derived from a Ph+ ALL patient: fundamental differences between Ph+ ALL and blastic CML. Cancer Genet. Cytogenet. 1985;18:49
  24. Kitano K, Sato Y, Suda T, Miura Y. Difference of cell lineage expression of hematopoietic progenitor cells in Philadelphia-positive acute lymphoblastic leukemia and chronic myelogenous leukemia. Br. J. Haematol. 1988;70:21
  25. Secker-Walker LM, Cooke HMG, Browett PJ, et al.  Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia. Blood. 1988;72:784
  26. Turhan AG, Eaves CJ, Kalousek DK, et al.  Molecular analysis of clonality and bcr rearrangements in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1988;71:1495
  27. Craig JM, Hawkins JM, Yamada T. First intron and M-bcr breakpoints are restricted to the lymphoid lineage in Philadelphia positive acute lymphoblastic leukemia. Leukemia. 1990;4:678
  28. Dow LW, Tachibana N, Raimondi SC, Lauer SJ, Witte ON, Clark SS. Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q11 variants. Blood. 1989;73:1291
  29. Tachibana N, Raimondi SC, Lauer SJ, et al.  Evidence for a multipotential stem cell in some childhood Philadelphia chromosome—positive acute lymphoblastic leukemias. Blood. 1987;70:1458
  30. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, et al.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker BCR/ABL with C3/A2 junction. Blood. 1996;88:2410
  31. Tuohy EL. A case of splenomegaly with polymorphonuclear neutrophil hyperleukocytosis. Am. J. Med. Sci. 1920;18:160
  32. Meyer S, Feremans W, Cantiniaux B, Capel P, Huygen R, Dicato M. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia (letter). Blood. 1993;82:1035
  33. Kwong YL, Cheng G. Clonal nature of chronic neutrophilic leukemia (letter). Blood. 1993;82:1035
  34. Melo JV. Bcr–Abl gene variants. Baillieres. Clin. Haematol. 1997;10:203
  35. Melo JV, Myint H, Galton DA, Goldman JM. P190 BCR–ABL chronic myeloid leukemia: the missing link with chronic myelomonocytic leukemia?. Leukemia. 1994;8:208
  36. Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, et al.  Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991;78:2411
  37. Saglio G, Pane F, Gottardi E, Frigeri F, Buonaiuto MR, Guerasio A, et al.  Consistent amounts of acute leukemia-associated P190 BCR/ABL transcripts are expressed by chronic myelogenous leukemia pateints at diagnosis. Blood. 1996;87:1075
  38. Saglio G, Pane F, Martinelli G, Guerrasio A. BCR/ABL rearrangement and leukemia phenotype. Leukemia. 1999;13(Suppl. 1):S96
  39. van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NCP. P190 BCR–ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996;87:5213
  40. Mills KI, MacKenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood. 1988;72:1237
  41. Mills KI, Sproul AM, Leibowitz D, Burnett AK. Mapping of breakpoints, and relationship to BCR–ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukemia patients with a breakpoint around exon 14 (b3) of the BCR gene. Leukemia. 1991;5:937
  42. Elliott SL, Taylor KM, Taylor DL, Rodwell RL, Williams BF, Shuttlewood MM, et al.  Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location. Leukemia. 1995;9:946
  43. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br. J. Haematol. 1995;89:546
  44. Fioretos T, Nilsson PG, Aman P, Heim S, Kirstoffersson U, Malm C, et al.  Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia. Leukemia. 1993;7:1225
  45. Rozman C, Urbano Ispizua A, Cervantes F, Rozman M, Colomer D, Feliz P, et al.  Analysis of the clinical relevance of the breakpoint location within M-bcr and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia. 1995;9:1104
  46. Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, Yamada T, et al.  A possible correlation between the type of bcr–abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 1991;78:3125
  47. Ardern JC, Speak J, Hyde K, Hunt LP, Lawson R, Gorst DW, et al.  Molecular analysis in chronic granulocytic leukemia: location of breakpoints within M-bcr and relationship with presentation platelet counts. Clin. Lab Hematol. 1993;15:253
  48. Martiat P, Ifrah N, Rassool F, Morgan G, Giles F, Gow J, et al.  Molecular analysis of Philadelphia positive essential thrombocythemia. Leukemia. 1989;3:563
  49. Cervantes F, Urbano Ispizua A, Villamor N, Feliu E, Milla F, Lopez Guillermo A, et al.  Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and termination into megakaryoblastic blast crisis: report of two cases with molecular studies. Leukemia. 1993;7:327
  50. Morris CM, Heisterkamp N, Groffen J, Fitzgerald PH. Entire ABL gene is joined with 5′-BCR in some patients with Philadelphia-positive leukemia. Blood. 1991;78:1078
  51. Cortez D, Reuther G, Pendergast AM. The Bcr–Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 1997;15:2333
  52. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al.  BCR–ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175
  53. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR–ABL-mediated transformation and inhibition of apoptosis. Mol. Cell. Biol. 1995;15:5531
  54. Salomoni P, Wasik MA, Riedel RF, Reiss K, Choi JK, Skorski T, et al.  Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant. J. Exp. Med. 1998;187:1995
  55. Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp. Hematol. 1994;22:1111
  56. Burgess GS, Williamson EA, Cripe LD, Litz-Jackson S, Bhatt JA, Stanley K, et al.  Regulation of the c-jun gene in p210 BCR–ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998;92:2450
  57. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901
  58. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR–ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247
  59. Ilaria RL, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 1996;271:31704
  60. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 1997;16:6151
  61. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS. A requirement for NF-kappaB activation in Bcr–Abl-mediated transformation. Genes Dev. 1998;12:968
  62. Sawyers CL, McLaughlin J, Witte ON. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr–Abl oncogene. J. Exp. Med. 1995;181:307
  63. Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD. Factor independence of human myeloid leukemia cells is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp. Hematol. 1994;22:1111
  64. Skorski T, Kanakaraj P, Nieborowska-Skorska M, et al.  Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 1995;86:726
  65. Skorski T, Bellacosa A, Nieborowska-Skorska M, et al.  Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway. EMBO J. 1997;16:6151
  66. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr–Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad Sci. USA. 1995;92:11746
  67. Dickens M, Rogers JS, Cavanaugh J, et al.  A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 1997;277:693
  68. Sawyers CL, Callahan W, Witte ON. Dominant negative Myc blocks transformation by ABL oncogenes. Cell. 1992;70:901–910
  69. Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr–Abl point mutants with c-Myc. Science. 1994;264:424
  70. Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, et al.  Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 1998;12:1415
  71. Evans CA, Owen-Lynch PJ, Whetton AD, Dive C. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells. Cancer Re. 1993;53:1735
  72. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824
  73. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr–abl oncogene products. Science. 1990;247:1079
  74. Wang JY. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr. Opin. Genet. Dev. 1993;3:35
  75. Raitano AB, Whang YE, Sawyers CL. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta. 1997;1333:F201
  76. Ghaffari S, Daley GQ, Lodish HF. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia. 1999;13:1200
  77. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR–ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161
  78. Howell BW, Gertler FB, Cooper JA. Mouse disabled (mDab1): a Src binding protein in neuronal development. EMBO J. 1997;16:121
  79. Yamanashi Y, Baltimore D. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein. Dok. Cell. 1997;88:205
  80. Carpino N, Wisniewski D, Strife A, et al.  P62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell. 1997;88:197
  81. Bhat A, Johnson KJ, Oda T, Corbin AS, Druker BJ. Interactions of p62(dok) with p210(bcr–abl) and Bcr–Abl associated proteins. J. Biol. Chem. 1998;273:32360
  82. Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ. Interactions of CBL with BCR–ABL and CRKL in BCR–ABL-transformed myeloid cells. J. Biol. Chem. 1997;272:16170
  83. Afar DE, Han L, McLaughlin J, et al.  Regulation of the oncogenic activity of BCR–ABL by a tightly bound substrate protein RIN1. Immunity. 1997;6:773
  84. Kapeller R, Moriarty A, Strauss A, et al.  Tyrosine phosphorylation of tub and its association with Src homology 2 domain-containing proteins implicate tub in intracellular signaling by insulin. J. Biol. Chem. 1999;274:24980
  85. Roumiantsev S, de Aos IE, Varticovski L, Ilaria R, Van Etten RA. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 2001;97:4
  86. Heisterkamp N, Voncken JW, Senadheera D, Gonzalez-Gomez I, Reichert A, Haataja L, et al.  Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants. Blood. 2000;96:2226
  87. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM. Novel therapies for chronic myelogenous leukemia. Exp. Hematol. 2001;29:543
  88. Afar DE, Goga A, Cohen L, et al.  Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR–ABL. Cold Spring Harbor Symp. Quant. Biol. 1994;59:589
  89. Afar DE, McLaughlin J, Sherr CJ, Witte ON, Roussel MF. Signaling by ABL oncogenes through cyclin D1. Proc. Natl. Acad Sci. USA. 1995;92:9540
  90. Jiang Y, Zhao RC, Verfaillie CM. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity. Proc. Natl. Acad Sci. USA. 2000;97:10538
  91. Sawyers CL. Molecular consequences of the BCR–ABL translocation in chronic myelogenous leukemia. Leuk Lymphoma. 1993;11:101
  92. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR–ABL in chronic myeloid leukemia. Blood. 1994;83:2038
  93. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR–ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83:1179
  94. Cotter TG. BCR–ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Leuk Lymphoma. 1995;18:231
  95. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad Sci. USA. 1987;84:6558
  96. Gishizky ML, Witte ON. Initiation of dysregulated growth of multipotent progenitor cells by bcr–abl in vitro. Science. 1992;256:836
  97. Chissoe SL, Bodenteich A, Wang YF, Wang YP, Burian D, Clifton SW, et al.  Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics. 1995;27:67
  98. Kurzrock R, Shtalrid M, Romero P, et al.  A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia. Nature. 1987;325:631
  99. Chan L, Karhi KK, Rayter SI, et al.  A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia. Nature. 1987;325:635
  100. Quackenbush RQ, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr–Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr–Abl tyrosine kinases. Blood. 2000;95:2913
  101. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR–ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol. Cell. Biol. 1989;9:1866
  102. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 1999;189:1399
  103. Nishimura J, Shibata K, Sadamura S, Takahira H, Hirata J, Umemura T, et al.  Differences in tyrosine phosphorylated proteins between cells expressing P210bcr/abl and P190bcr/abl. Int. J. Hematol. 1992;55:227
  104. de Jong R, van Wijk A, Haataja L, Heisterkamp N, Groffen J. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl. J. Biol. Chem. 1997;272:32649
  105. Okuda K, Golub TR, Gilliland DG, Griffin JD. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996;13:1147
  106. Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R. Rac, a novel ras-related family of proteins that are botulinum toxin substrates. J. Biol. Chem. 1989;264:16378
  107. McWhirter JR, Wang JY. Effect of Bcr sequences on the cellular function of the Bcr–Abl oncoprotein. Oncogene. 1997;15:1625
  108. Daley GQ, Ben-Neriah Y. Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. Adv. Cancer Res. 1991;57:151
  109. Chuang T-H, Xu X, Kaartinen V, Heisterkamp N, Groffen J, Bokoch G. Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family. Proc. Natl. Acad Sci. USA. 1995;92:10282
  110. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389
  111. Estrov Z, Talpaz M, Kantarjian H, Zipf T, McClain KL, Kurzrock R. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190 BCR–ABL or p210 BCR–ABL: determination by analysis of individual colonies with the polymerase chain reaction. Cancer Res. 1993;53:3289
  112. Kalousek DK, Dube ID, Eaves CJ, Eaves AC. Cytogenetic studies of hemopoietic colonies from patients with an initial diagnosis of acute lymphoblastic leukemia. Br. J. Hematol. 1988;70:5
  113. Kantarjian HM, Talpaz M. Definition of the accelerated phase of chronic myelogenous leukemia. J. Clin. Oncol. 1988;6:18
  114. Nanjangud G, Kadam PR, Saikia T, Bhisey AN, Kumar A, Gopal R, et al.  Karyotypic findings as an independent prognostic marker in chronic myeloid leukemia blast crisis. Leuk Res. 1994;18:385
  115. Asou N, Sanada I, Tanaka K, Hidaka M, Suzushima H, Matsuzaki H, et al.  Inversion of chromosome 16 and bone marrow eosinophilia in a myelomonocytic transformation of chronic myeloid leukemia. Cancer Genet Cytogenet. 1992;61:197
  116. Chopra R, Pu QQ, Elefanty AG. Biology of BCR–ABL. Blood Rev. 1999;13:211
  117. Cogswell PC, Morgan R, Dunn M. Mutations in the ras proto-oncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood. 1989;74:2629
  118. Feinstein E, Cimino G, Gale RP. P53 in chronic myelogenous leukemia in acute phase. Proc. Natl. Acad Sci. USA. 1991;88:6293
  119. Sawyers CL. The role of myc in transformation by BCR–ABL. Leuk Lymphoma. 1993;11(Suppl. 1):45
  120. Ahuja H, Bar-Eli M, Arlin Z. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J. Clin. Invest. 1991;87:2042
  121. Towatari M, Aduchi K, Kato H, Saito H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood. 1991;78:2178
  122. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. BCR–ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene. 1998;16:335
  123. Collins SJ, Kubonishi I, Miyoshi I, Groudine MT. Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science. 1984;225:72
  124. Andrews DF, Collins SJ. Heterogeneity in expression of the bcr–abl fusion transcript in CML blast crisis. Leukemia. 1987;1:718
  125. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, et al.  Increase of bcr–abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood. 1995;86:2371
  126. Beck Z, Bacsi A, Kovacs E, Kiss J, Kiss A, Balogh E, et al.  Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration. Leuk Lymphoma. 1998;30:293
  127. Mitelman F. They cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma. 1993;11:11
  128. Liu E, Hjelle B, Bishop JM. Transforming genes in chronic myelogenous leukemia. Proc. Natl. Acad Sci. USA. 1988;85:1952
  129. O’Bryan JP, Frye RA, Cogswell PC, et al.  Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol. Cell. Biol. 1991;11:501
  130. Rowley DJ, Testa JR. Chromosome abnormalities in malignant hematologic disease. Adv. Cancer Res. 1982;36:103
  131. Mauro MJ, Druker BJ. Chronic myelogenous leukemia. Curr. Opin. Oncol. 2001;13:3
  132. Chronic Myeloid Leukemia Trialists’ Cooperative Group. Interferon-alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997;89:1616.
  133. Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996;17(Suppl. 3):S7
  134. Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, et al.  Polymerase chain reaction detection of the bcr–abl fusion transcript after allogeneic marrow transplantation for chronic meyloid leukemia—results and implications in 346 patients. Blood. 1995;85:2632
  135. Lion T, Gaiger A, Henn T, Horth E, Haas OA, Geissler K, et al.  Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia. 1995;9:1353
  136. Giralt SA, Kolb HJ. Donor lymphocyte infusions. Curr. Opin. Oncol. 1996;8:96
  137. Oda T, Tamura S, Matsuguchi T, Griffin JD, Druker BJ. The SH2 domain of ABL is not required for factor-independent growth induced by BCR–ABL in a murine myeloid cell line. Leukemia. 1995;9:295
  138. Buchdunger E, Zimmermann J, Mett H, et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100
  139. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938
  140. Druker BJ, Tamura S, Buchdunger E, et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nat Med. 1996;2:561
  141. Druker BJ, Sawyers CL, Talpaz M. Phase I trial of specific abl tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients. Proc. ASCO. 1999;8:24a (abstract)
  142. Talpaz M, Sawyers CL, Kantarjian HM, et al. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR–ABL positive acute leukemia, including chronic myelogenous leukemia in blast crisis. Proc ASCO 2000;19:4a (abstract).
  143. Goldman JM, Melo JV. Targeting the BCR–ABL tyrosine kinase in chronic myeloid leukemia (letter). N. Engl. J. Med. 2001;344:1084
  144. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV, Selection and characterization of BCR–ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96 (3):1070–9.
  145. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000;95:3498
  146. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al.  Clinical resistance in STI-571 cancer treatment caused by Bcr–Abl gene mutation or amplification. Science. 2001;293:876
  147. Lim Y-M, Wong S, Lau G, Witte ON, Colicelli J. BCR/ABL inhibition by an escort/phosphatase fusion protein. Proceedings of the National Academy of Sciences of the USA. Proc Natl Acad Sci USA. 2000;97:12233
  148. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, et al.  Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404

PII: S0145-2126(01)00197-7

Leukemia Research
Volume 26, Issue 8 , Pages 713-720 , August 2002

Article Tools

* Image Usage & Resolution